- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Drug Evaluation and Research
FDA is issuing this guidance to help sponsors of human drugs, including those that are biological products, develop proprietary names2 that do not cause or contribute to medication errors or otherwise contribute to the misbranding of the drug. This guidance describes design practices to help avoid such errors with proprietary names and provides a qualitative systematic framework for evaluating proposed proprietary names before submitting them for FDA review. This guidance does not address the selection of established names or proper names.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2014-D-0622.